
Journal of Clinical Oncology

The Official Journal of the American Society of Clinical Oncology

Vol 12, No 8

August 1994

CONTENTS

EDITORIAL: Gemcitabine: Current Status of Phase I and II Trials *S.B. Kaye* 1527

EDITORIAL: Attainment of Molecular Remission: A Worthwhile Goal?
John G. Gribben 1532

ORIGINAL REPORTS

Efficacy and Safety Profile of Gemcitabine in Non-Small-Cell Lung Cancer: A Phase II Study *Raymond P. Abratt, Werner R. Bezwoda, Geoffrey Falkson, Louis Goedhals, Dayle Hacking, and Terence A. Rugg* 1535

Clinical Significance of t(14;18)-Positive Cells in the Circulation of Patients With Stage III or IV Follicular Non-Hodgkin's Lymphoma During First Remission *A.C. Lambrechts, P.E. Hupkes, L.C.J. Dorssers, and M.B. van't Veer* 1541

Role of Radiotherapy in Combined Modality Treatment of Locally Advanced Non-Small-Cell Lung Cancer *Kaoru Kubota, Kiyoyuki Furuse, Masaaki Kawahara, Nagahisa Kodama, Masunari Yamamoto, Mitsumasa Ogawara, Shunichi Negoro, Noriyuki Masuda, Minoru Takada, Kaoru Matsui, Nobuhide Takifuji, Shinzoh Kudoh, Yoko Kusunoki, and Masahiro Fukuoka* 1547

Multiinstitutional Phase II Trial of Intensive Combination Chemoimmunotherapy for Metastatic Melanoma *Michael B. Atkins, Kevin R. O'Boyle, Jeffrey A. Sosman, Geoffrey R. Weiss, Kim A. Margolin, Mary Lou Ernest, Kerry Kappler, James W. Mier, Joseph A. Sparano, Richard I. Fisher, John R. Eckardt, Cindy Pereira, and Frederick R. Aronson* 1553

Phase I/II Study of Iodine 131-Labeled Monoclonal Antibody A33 in Patients With Advanced Colon Cancer *Sydney Welt, Chaitanya R. Divgi, Nancy Kemeny, Ronald D. Finn, Andrew M. Scott, Martin Graham, Jean St. Germain, Elizabeth Carswell Richards, Steven M. Larson, Herbert F. Oettgen, and Lloyd J. Old* 1561

Journal of Clinical Oncology (ISSN 0732-183X) is published monthly by W.B. Saunders Company, Corporate and Editorial Offices: The Curtis Center, Independence Square West, Philadelphia, PA 19106-3399. Accounting and Circulation Offices: W.B. Saunders Company, 6277 Sea Harbor Dr, Orlando, FL 32887-4800. Second class postage paid at Orlando, FL 32862, and at additional mailing offices.

POSTMASTER: Send change of address to *Journal of Clinical Oncology*, c/o W.B. Saunders Company, 6277 Sea Harbor Dr, Orlando, FL 32887-4800.

Yearly subscription rates: United States and possessions: individuals, \$181.00; institutions, \$231.00; single issues, \$31.00. All other countries: individuals, \$235.00; institutions, \$276.00; single issues, \$31.00. Students and residents: United States and possessions, and Canada: \$76.00, all other countries: \$88.00. To receive student/resident rate, orders must be accompanied by name of affiliated institution, date of term, and the signature of program/residency coordinator on institution letterhead. Orders will be billed at individual rate until proof of status is received. Current prices are in effect for back volumes and back issues. Back issues sold in conjunction with a subscription are on a prorated basis. Subscriptions are accepted on a calendar year basis. Prices are subject to change without notice. Single issues, both current and back, exist in limited quantities and are offered for sale subject to availability.

Randomized Comparison of High-Dose and Low-Dose Intravenous Interleukin-2 for the Therapy of Metastatic Renal Cell Carcinoma: An Interim Report	<i>James C. Yang, Suzanne L. Topalian, David Parkinson, Douglas J. Schwartzentruber, Jeffrey S. Weber, Stephen E. Ettinghausen, Donald E. White, Seth M. Steinberg, David J. Cole, Hyun I. Kim, Richard Levin, Anshu Guleria, Mark P. MacFarlane, Richard L. White, Jan H. Einhorn, Claudia A. Seipp, and Steven A. Rosenberg</i>	1572
Incidence of Multiple Myeloma in Olmsted County, Minnesota: 1978 Through 1990, With a Review of the Trend Since 1945	<i>Robert A. Kyle, C. Mary Beard, W. Michael O'Fallon, and Leonard T. Kurland</i>	1577
Clinical Modulation of Multidrug Resistance in Multiple Myeloma: Effect of Cyclosporine on Resistant Tumor Cells	<i>P. Sonneveld, M. Schoester, and K. de Leeuw</i>	1584
Tumor Response, Toxicity, and Survival After Neoadjuvant Organ-Preserving Chemotherapy for Advanced Laryngeal Carcinoma	<i>Monica B. Spaulding, Susan G. Fischer, Gregory T. Wolf, and the Department of Veterans Affairs Cooperative Laryngeal Cancer Study Group</i>	1592
Correlation of DNA Content of Laryngeal Epithelial Lesions to Degree of Malignancy	<i>Angel Ispizua, Antonio Baroja, and Carmen de la Hoz</i>	1600
Survival of Infants With Primitive Neuroectodermal Tumors or Malignant Ependymomas of the CNS Treated With Eight Drugs in 1 Day: A Report From the Childrens Cancer Group	<i>J. Russell Geyer, Paul M. Zeltzer, James M. Boyett, Lucy B. Rorke, Philip Stanley, A. Leland Albright, Jeffrey H. Wisoff, Jerrold M. Milstein, Jeffrey C. Allen, Jonathan L. Finlay, Gregory D. Ayers, Susan B. Shurin, Kenneth R. Stevens, and W. Archie Bleyer</i>	1607
Phase II Investigational Window Using Carboplatin, Iproplatin, Ifosfamide, and Epirubicin in Children With Untreated Disseminated Neuroblastoma: A Pediatric Oncology Group Study	<i>R.P. Castleberry, A.B. Cantor, A.A. Green, V. Joshi, R.L. Berkow, G.R. Buchanan, B. Leventhal, D.H. Mahoney, E.I. Smith, and F.A. Hayes</i>	1616
Paclitaxel in Doxorubicin-Refractory or Mitoxantrone-Refractory Breast Cancer: A Phase I/II Trial of 96-Hour Infusion	<i>Wyndham H. Wilson, Stacey L. Berg, George Bryant, Robert E. Wittes, Susan Bates, Antonio Fojo, Seth M. Steinberg, Barry R. Goldspiel, Jean Herdt, Joyce O'Shaughnessy, Frank M. Balis, and Bruce A. Chabner</i>	1621
Tamoxifen Versus High-Dose Oral Medroxyprogesterone Acetate as Initial Endocrine Therapy for Patients With Metastatic Breast Cancer: A Piedmont Oncology Association Study	<i>Hyman B. Muss, L. Douglas Case, James N. Atkins, James D. Bearden III, M. Robert Cooper, Julia M. Cruz, Don V. Jackson, Jr, Mark A. O'Rourke, Michael D. Pavy, Bayard L. Powell, Frederick Richards II, Charles L. Spurr, Kaye Eagle, and Douglas R. White</i>	1630
Salvage Therapies in Women Who Fail to Respond to First-Line Treatment With Fluorouracil, Epirubicin, and Cyclophosphamide for Advanced Breast Cancer	<i>Kimmo Porkka, Carl Blomqvist, Pentti Rissanen, Inkeri Elomaa, and Seppo Pyrhönen</i>	1639
Plasminogen Activator Inhibitor-1 and Prognosis in Primary Breast Cancer	<i>John A. Foekens, Manfred Schmitt, Wim L.J. van Putten, Harry A. Peters, Michael D. Kramer, Fritz Jänicke, and Jan G.M. Klijn</i>	1648

Comparative Study of the Pharmacokinetics and Toxicity of High-Dose Epirubicin With or Without Dexrazoxane in Patients With Advanced Malignancy	<i>Russell Lindsay Basser, Mordechai Motty Sobol, Geraint Duggan, Jonathan Cebon, Mark Andrew Rosenthal, George Mihaly, and Michael David Green</i>	1659
Patient Characteristics Associated With High-Risk Methotrexate Concentrations and Toxicity	<i>Mary V. Relling, Diane Fairclough, Dan Ayers, William R. Crom, John H. Rodman, Ching-Hon Pui, and William E. Evans</i>	1667
Non-Hodgkin's Lymphoma of the Gastrointestinal Tract: A Population-Based Analysis of Incidence, Geographic Distribution, Clinicopathologic Presentation Features, and Prognosis	<i>F. d'Amore, H. Brincker, K. Grønbaek, K. Thorling, M. Pedersen, M.K. Jensen, E. Andersen, N.T. Pedersen, and L.S. Mortensen for the Danish Lymphoma Study Group</i>	1673
Sequential High-Dose Therapy With Peripheral-Blood Progenitor-Cell Support in Low-Grade Non-Hodgkin's Lymphoma	<i>R. Haas, M. Moos, A. Karcher, R. Möhle, B. Witt, H. Goldschmidt, S. Frühauf, M. Flentje, M. Wannenmacher, and W. Hunstein</i>	1685
Development of a Simplified Single-Apheresis Approach for Peripheral-Blood Progenitor-Cell Transplantation in Previously Treated Patients With Lymphoma	<i>H.M. Jones, S.A. Jones, M.J. Watts, A. Khwaja, W. Mills, A. Fielding, A.H. Goldstone, and D.C. Linch</i>	1693
Transient Acantholytic Dermatitis in Oncology Patients	<i>Adriana L. Guana and Philip R. Cohen</i>	1703

REVIEW ARTICLES

Leukemia: Management of Relapse After Allogeneic Bone Marrow Transplantation	<i>Lalit Kumar</i>	1710
The Community Clinical Oncology Program (CCOP) Story: Review of Community Oncologists' Experiences With Clinical Research Trials in Cancer With an Emphasis on the CCOP of the National Cancer Institute Between 1982 and 1987	<i>Robert W. Frelick</i>	1718

SPECIAL ARTICLE

Quantitating Familial Cancer Risk: A Resource for Clinical Oncologists	<i>Kenneth Offit and Karen Brown</i>	1724
---	--------------------------------------	------

SPECIAL DEPARTMENTS

Correspondence		1737
Bone Marrow Transplant in Acute Myeloid Leukemia	<i>Donald Pinkel</i>	
• In Reply	<i>Jonathan Buckley and Mark E. Nesbit</i>	
Prognostic Factors for Women With Ovarian Germ Cell Tumors	<i>Jose I. Mayordomo, Luis Paz-Ares, Maria T. Diaz-Puente, Pilar Lianes, Maria D. Garcia-Prats, and Hernan Cortes-Funes</i>	
• In Reply	<i>Eva Segelov and Michael Friedlander</i>	

Clarification of Entry Criteria for the European Organization for Research and Treatment of Cancer

H5-Favorable Trial of Early-Stage Hodgkin's Disease *Gregory M. Rasp, Michael G. Haddock,
and James A. Martenson*

• In Reply *Patrice Carde*

Calvert's Formula and High-Dose Carboplatin *Beatrice Uziely, Silvia C. Formenti, Kristy Watkins,
Amitabha Mazumder, and Franco M. Muggia*

Photopsia During 3-Hour Paclitaxel Administration at Doses ≥ 250 mg/m² *Andrew D. Seidman,
Scott Barrett, and Socorro Canezo*

Announcements lxi

Information for Contributors xvii

Current Abstracts xvi

ASCO Abstract Form B1